INTRODUCTION {#S0001}
============

Estetrol (E~4~) is a naturally occurring estrogen discovered in 1965^[@CIT0001]^. E~4~ is produced exclusively and in large amounts by the human fetal liver. E~4~ has a relatively low affinity for the estrogen receptor (ER), but this is largely compensated by its high oral bioavailability (80% in contrast to 1% for estradiol \[E~2~\]) and a long half-life of approximately 28 h (in contrast to 3.6 h for E~2~). It binds to both ERα and ERβ, with a four- to fivefold preference for ERα. After its initial discovery, research on E~4~ was performed for approximately 20 years in unsuccessful attempts to discover its function or to correlate its maternal plasma levels with fetal well-being. Thereafter, scientific interest in the hormone declined. In recent years, preclinical and clinical therapeutic studies have shown that E~4~ might be an effective drug for several indications, including contraception, as it was notably shown to inhibit ovulation in cycling rats in a dose-dependent manner^[@CIT0002],[@CIT0003]^.

Some evidence suggests that E~4~ may be suitable as a daily oral contraceptive and has several benefits in comparison with the currently available estrogen. Most marketed combined oral contraceptives (COCs) contain the potent synthetic estrogen ethinylestradiol (EE). EE has been shown to be safe but causes subjective side effects and increases the hepatic production of several coagulation factors, resulting in a prothrombotic status^[@CIT0004]^. The most serious adverse effects of EE are cardiovascular complications, both arterial and venous, and in particular an increased risk of venous thromboembolism (VTE)^[@CIT0005],[@CIT0006]^. These cardiovascular complications are rare but serious, especially when they occur in young, healthy women. The risk of VTE has been reduced by decreasing the EE dosage in COCs and it could also be lowered by replacing EE with the natural estrogen E~2~. There are currently two COCs on the market that contain E~2~ instead of EE: a sequential COC containing estradiol valerate (E~2~V) and dienogest (DNG) and a monophasic COC containing E~2~ and nomegestrol acetate. Recent epidemiological data suggest that the risk of VTE for users of COCs containing E~2~V and DNG is similar to that for users of COCs containing second-generation progestins^[@CIT0007]^. Because E~4~ has minimal impact on the hepatic production of coagulation factors, it is hypothesised that the VTE risk will also be reduced by using the natural estrogen E~4~ instead of EE \[Kluft C, *et al.*, submitted\].

In addition, in contrast to EE or E~2~, E~4~ does not inhibit the cytochrome P450 enzymes and should consequently not interfere with the metabolism of other drugs^[@CIT0008]^. It is excreted in the urine as inactive sulfo- and glucurono-conjugates that do not interfere with the biliary system and therefore would not increase the incidence of gallbladder diseases as do classical COCs^[@CIT0009]^. E~4~ metabolism has not been shown to produce active metabolites, in contrast to E~2~, whose metabolism leads to the production of carcinogenic catechol estrogen metabolites^[@CIT0010]^. Finally, recent clinical and experimental *in vitro* and animal studies demonstrate a minimal impact of E~4~ on normal and malignant breast cells^[@CIT0011]^.

The present study was performed to investigate the effects of different doses of E~4~ in combination with two different progestins, drospirenone (DRSP) and levonorgestrel (LNG), on ovarian follicular activity and ovulation, in comparison to the registered COC EE/DRSP (Yaz; Bayer HealthCare Pharmaceuticals, Berlin, Germany). In addition, pituitary--ovarian function, the effect on endometrial thickness and the return of ovulation were investigated.

METHODS {#S0002}
=======

This single centre, open, parallel, phase II, dose-finding pilot study was performed on a limited number of healthy female volunteers. The study was conducted in a clinical research centre (Dinox BV) in Groningen, the Netherlands. The trial was registered in the Netherlands Trial Register ([www.trialregister.nl](http://www.trialregister.nl)) under the registration number NTR2102. Compliance with Good Clinical Practice and the statistical and clinical study report were verified by an independent auditor.

Participants {#S0003}
------------

All trial participants gave their written informed consent, and the study was approved by the independent ethics committee Stichting Therapeutische Evaluatie Geneesmiddelen (Duivendrecht, the Netherlands). The main inclusion criteria were as follows: age 18 to 35 years; ovulation in the pretreatment cycle between cycle day 9 (± 1) and day 24 (± 1), with a subsequent progesterone concentration ≥ 16 nmol/l and a luteal phase duration of at least 6 (± 1) days; body mass index (BMI) of 18 to 30 kg/m^[@CIT0002]^; and good physical and mental health. Exclusion criteria were as follows: contraindication for contraceptive steroids; clinically relevant abnormal laboratory results; a long duration of the washout cycle after stopping hormonal contraception for more than 42 days; pregnancy; lactation; pregnancy during accurate hormonal contraceptive use in the past; history of breast cancer; abnormalities of the uterus or ovaries; abnormal cervical smear in the last 3 years or at screening; renal insufficiency; hepatic dysfunction; adrenal insufficiency; status postpartum or postabortion in the last 2 months; and a history (within 12 months) of alcohol or drug abuse. Use of the following drugs within two cycles prior to the start of study medication were also exclusion criteria: hepatic enzyme-inducing medicinal products; sex steroids; herbal remedies containing St John\'s Wort; antihypertensive drugs; phytoestrogens; investigational drugs in the last 2 months; and an injectable hormonal method of contraception in the last 6 months.

Before inclusion in the study, all participants underwent a general physical and gynaecological examination, including electrocardiogram, transvaginal ultrasonography (TVUS), breast examination and cervical smear (if no smear result had been obtained within the last 3 years). Haematological and clinical chemical blood parameters were determined, and urinalysis was performed.

The participants received financial compensation for their participation in the trial.

Study design {#S0004}
------------

Participants who were using hormonal contraception at the start of the study discontinued its use after completion of the current cycle and then had a washout cycle. All participants had to use barrier contraception methods throughout the study. The pretreatment cycle started on the first day of spontaneous menstrual blood loss after the washout cycle (if any). Participation in the study was accepted only if ovulation occurred on or before day 24 (± 1) of the pretreatment cycle, if the progesterone concentration was ≥ 16 nmol/l and if the next menstruation did not start within 6 (± 1) days after ovulation. Eligibility was evaluated by monitoring follicular growth in the pretreatment cycle by TVUS, which was performed every 3 (± 1) days. After ovulation was documented by TVUS, a blood sample was taken 2 (± 1) days later to determine the progesterone concentration. If the progesterone concentration was in the postovulatory range but below 16 nmol/l another blood sample was taken 4 (± 1) days after ovulation.

During the first and the third treatment cycles, TVUS and blood sampling were performed every third (± 1) day from day 3 (± 1) to day 24 (± 1). TVUS and blood sampling were also performed on day 3 (± 1) of the second cycle. If a follicle with a diameter ≥ 13 mm was observed at day 24 (± 1) of the first or third cycle or at day 3 (± 1) of the second cycle, TVUS and blood sampling were continued every 3 (± 1) days until the follicle disappeared.

During the spontaneous cycle following the three treatment cycles, TVUS was performed every third (± 1) day from day 3 onwards until ovulation was observed. A blood sample was taken 2 (± 1) days after ovulation to determine the progesterone concentration. If the progesterone concentration was in the postovulatory range but below 16 nmol/l, another blood sample was taken 4 (± 1) days after ovulation. A follow-up visit was performed on day 3 (± 1) of the cycle after the post-treatment cycle. At the follow-up visit, physical and gynaecological examinations were performed.

Urine pregnancy tests were performed before the first intake of study medication and several times during the course of the study. Haematological and clinical chemical blood determinations and urinalysis were performed at screening and during the post-treatment cycle. At all visits during the study, participants were questioned for adverse events and use of concomitant medication.

Treatment {#S0005}
---------

There were six treatment groups: (i) 5 mg E~4~ combined with 3 mg DRSP (5 mg E~4~/DRSP); (ii) 10 mg E~4~ combined with 3 mg DRSP (10 mg E~4~/DRSP); (iii) 20 μg EE combined with 3 mg DRSP (EE/DRSP); (iv) 5 mg E~4~ combined with 150 μg LNG (5 mg E~4~/LNG); (v) 10 mg E~4~ combined with 150 μg LNG (10 mg E~4~/LNG); and (vi) 20 mg E~4~ combined with 150 μg LNG (20 mg E~4~/LNG). All participants were stratified according to the day of ovulation in the pretreatment cycle and then assigned to one of the treatment groups. E~4~ was supplied as tablets of 5 or 10 mg, in blister packs. DRSP was supplied as tablets of 3 mg, and LNG as tablets of 150 μg, both in blister packs. EE/DRSP was supplied as tablets in the original blister pack. Blinding was therefore not possible.

Production, packaging and labelling of the study medication were performed according to Good Manufacturing Practice guidelines (Haupt Pharma, Münster, Germany). The chemical synthesis of E~4~ was performed by Cambridge Major Laboratories Europe (Weert, the Netherlands). A quality control of the tablets was performed at their release, and studies were conducted to evaluate the stability of the products for periods of time beyond the duration of the study. Oral treatment was started on the first day of menstruation following the pretreatment cycle and was administered for three cycles once daily in the morning at approximately the same time, which was recorded in a diary. In each cycle, participants treated with E~4~ used the study medication for 24 days, followed by 4 days without medication. Participants treated with EE/DRSP used 24 active tablets followed by four placebo tablets.

Measurements {#S0006}
------------

TVUS was performed using a Voluson E8 device (GE Healthcare, Kretztechnik GmbH & Co OHG, Zipf, Austria). The mean diameter of the bidirectional measurement of the largest follicle in each ovary and the double-layer endometrial thickness were assessed. Serum levels of follicle-stimulating hormone (FSH), luteinising hormone (LH), E2 and progesterone were determined in each blood sample. Blood samples were processed to serum and stored at − 20°C until assays were performed. FSH, LH and progesterone levels in serum were determined by the Immulite 2000 immunoassay system (Siemens Healthcare GmbH, Erlangen, Germany). Because of significant crossreactivity between E~4~ and E~2~ using the commercially available ligand-binding assay, the E~2~ concentrations were determined using the API 4000 LC/MS/MS system (Applied biosystems/MSD Sciex, Waltham, MA, USA).

At several time points in the study, extra blood samples were taken to measure various liver parameters. In addition, bone turnover markers and growth endocrine parameters were determined, and pharmacokinetic parameters were measured in the blood and urine. The methods and results of these assessments will be reported separately.

Sample size {#S0007}
-----------

The study was explorative. Its aim was to gather information that would help to decide which dose regimen should be selected for future studies. Therefore, the sample size was not calculated but arbitrarily assigned to 18 women per group. Based on this sample size, the upper limit of the unidirectional confidence interval of the ovulation rate in the absence of ovulation would be 5% when considering no intra-subject correlation (i.e., no ovulation in any of the three treatment cycles for the same participant) or 14% when considering perfect intra-subject correlation (i.e., one ovulation in each treatment cycle for the same participant). This sample size was considered acceptable for a dose-finding pilot study.

Analysis {#S0008}
--------

The primary efficacy variable was the ovulation rate, i.e., the number of ovulations per number of cycles per treatment group. Ovulation was defined using the Hoogland score, which is based on the combination of maximum follicular diameter and concentrations of E~2~ and progesterone during a treatment cycle^[@CIT0014]^ ([Figure 1A](#F0001){ref-type="fig"}). Hoogland scores were determined for treatment cycles 1 and 3. In addition, summary statistics of the largest follicle size per time point and the maximum follicle size per participant over the entire treatment period were calculated.

![Ovulation inhibition according to the Hoogland score (A). Hoogland scores obtained during cycle 1 (B) and cycle 3 (C) with the different combinations tested during the trial. Results are expressed in percentage of participants.](iejc_a_1074675_f0001_b){#F0001}

Secondary study objectives were to investigate pituitary--ovarian function, effect on endometrial thickness and return of ovulation. The mean and maximum serum concentrations of E~2~, progesterone, FSH and LH per cycle were calculated. Summary statistics were calculated for the maximum endometrial thickness per woman per cycle. The return of ovulation was evaluated by assessing the day of ovulation in the post-treatment cycle.

Differences in the maximum follicle diameter and endometrial thickness for treatment cycles 1 and 3, comparing the E~4~ groups versus EE/DRSP, the different E~4~ dose groups and DRSP versus LNG, were analysed using a random effects repeated measures model. Hormone concentrations on day 3 of cycle 1 and pooled results on day 24 in cycles 1 and 3 were analysed statistically using a random effects repeated measures analysis model with pretreatment day 3 values as covariate after logarithmic transformation. Differences in the return of ovulation day comparing the E~4~ groups with the EE/DRSP group, comparing the different E~4~ doses, and comparing DRSP with LNG were analysed by analysis of covariance with day of ovulation in the pretreatment cycle as the covariate. In the statistical analyses, *p \<*0.01 was used as the criterion for statistical significance.

RESULTS {#S0009}
=======

Study population {#S0010}
----------------

The study was performed between November 2009 and November 2010. In total, 210 women were screened: 99 were screening failures and 111 were included and assigned to a treatment group. The most common reasons for screening failure were menstrual cycle deviations, in particular a washout cycle of more than 42 days after stopping COC, no ovulation until cycle day 24 in the pretreatment cycle, or a low progesterone concentration after ovulation in the pretreatment cycle. The participant disposition is shown in [Figure 2](#F0002){ref-type="fig"}.

![Participant disposition by treatment group.](iejc_a_1074675_f0002_b){#F0002}

The demographic and pretreatment cycle characteristics were generally similar across the treatment groups ([Table 1](#T0001){ref-type="table"}). However, compared with the other groups, the mean BMI was lower in the 5 mg E~4~/LNG and 10 mg E~4~/LNG groups, and the percentage of smokers was lower in the 10 mg E~4~/LNG and 20 mg E~4~/LNG groups.

###### Demographic and baseline characteristics.

  *Parameter*                                   *5 mg E4/DRSP (n = 19)*   *10 mg E4/DRSP (n = 19)*   *20 μg EE/DRSP (n = 20)*   *5 mg E4/LNG (n = 18)*   *10 mg E4/LNG (n = 17)*   *20 mg E4/LNG (n = 18)*   *Overall (n = 111)*
  --------------------------------------------- ------------------------- -------------------------- -------------------------- ------------------------ ------------------------- ------------------------- ---------------------
  Mean age, years (SD)                          24.3 (3.11)               23.7 (3.67)                23.4 (3.87)                22.3 (2.65)              22.4 (2.42)               21.1 (2.30)               22.9 (3.20)
  BMI, kg/m^[@CIT0002]^                                                                                                                                                                                      
   Mean (SD)                                    22.54 (2.33)              23.20 (3.21)               23.03 (2.93)               21.51 (1.70)             21.78 (2.52)              24.28 (3.37)              22.74 (2.83)
   Range                                        18.3--26.1                18.8--30.0                 19.2--28.3                 18.2--24.5               18.7--27.4                19.1--29.8                18.2--30.0
  Race, *n* (%)                                                                                                                                                                                              
   White or Caucasian                           16 (84.2)                 18 (94.7)                  19 (95.0)                  16 (88.9)                17 (100)                  16 (88.9)                 102 (91.9)
   Black or African American                    1 (5.3)                   0                          0                          0                        0                         2 (11.1)                  3 (2.7)
   Asian                                        2 (10.5)                  0                          1 (5.0)                    0                        0                         0                         3 (2.7)
   Other                                        0                         1 (5.3)                    0                          2 (11.1)                 0                         0                         3 (2.7)
  Mean duration of menstrual cycle, days (SD)   28.8 (1.81)               28.3 (0.75)                28.7 (1.29)                27.8 (2.13)              28.0 (0.38)               28.5 (3.22)               28.4 (1.86)
  Gravidity, *n* (%)                                                                                                                                                                                         
   0                                            14 (73.7)                 18 (94.7)                  19 (95.0)                  18 (100.0)               16 (94.1)                 16 (88.9)                 101 (91.0)
   ≥ 1                                          5 (26.3)                  1 (5.3)                    1 (5.0)                    0 (0.0)                  1 (5.9)                   2 (11.1)                  10 (9.0)
  Parity, *n* (%)                                                                                                                                                                                            
   0                                            16 (84.2)                 19 (100)                   19 (95.0)                  18 (100.0)               17 (100.0)                17 (94.4)                 106 (95.5)
   ≥ 1                                          3 (15.8)                  0 (0.0)                    1 (5.0)                    0 (0.0)                  0 (0.0)                   1 (5.6)                   5 (4.5)
  Smoking habits, *n* (%)                                                                                                                                                                                    
   Non-smoker                                   12 (63.2)                 13 (68.4)                  12 (60.0)                  11 (61.1)                14 (82.4)                 15 (83.3)                 77 (69.4)
   Smoker                                       5 (26.3)                  5 (26.3)                   7 (35.0)                   6 (33.3)                 3 (17.6)                  3 (16.7)                  29 (26.1)
   Former smoker                                2 (10.5)                  1 (5.3)                    1 (5.0)                    1 (5.6)                  0 (0.0)                   0 (0.0)                   5 (4.5)

SD, standard deviation

Ovulation rate {#S0011}
--------------

The distribution of the Hoogland scores in treatment cycles 1 and 3 in the different treatment groups is depicted in [Figure 1B](#F0001){ref-type="fig"} & 1C. In none of the treatment cycles was the Hoogland score higher than 4, so there were no luteinised unruptured follicles (LUFs) or ovulations. During treatment cycle 1, in all treatment groups, the majority (80% or more) of participants had no ovarian activity (Hoogland score 1) or potential activity (Hoogland score 2). The remaining participants had a non-active follicle-like structure (FLS) (Hoogland score 3) or active FLS (Hoogland score 4). For the E~4~ treatment groups, the number of participants with non-active FLS or active FLS was higher in treatment cycle 3 compared with treatment cycle 1. During treatment cycle 3, the majority (50% or more) of the participants had no activity or potential activity. Despite the low number of participants in each group, it appears that increasing the dose of E~4~ was associated with an increased suppression of ovarian activity, particularly in treatment cycle 3, during which the percentage of participants with non-active FLS or active FLS was lowest in the 20 mg E~4~/LNG group (12.6%) and comparable to the EE/DRSP group (0%).

Ovarian and pituitary function {#S0012}
------------------------------

The maximum values of the largest follicular diameter during the entire treatment period are shown in [Figure 3A](#F0003){ref-type="fig"}. The mean values of the largest follicular diameter at each time point during treatment cycles 1 and 3 are depicted in [Figure 3B](#F0003){ref-type="fig"}.

![Mean (± SD), minimum and maximum value of the largest follicular diameter per participant in each group over the entire treatment period (A). Mean diameter of the largest follicle (mm) measured in each treatment group every 3 days during cycles 1 and 3 (B).](iejc_a_1074675_f0003_b){#F0003}

The mean maximum follicular diameter in treatment cycle 1 and 3 decreased significantly with increasing E~4~ dose (*p* \< 0.0001) and did not differ between the DRSP and the LNG groups. The mean maximum follicular diameter in the 5 mg E~4~ groups was higher than in the EE/DRSP group (*p* \< 0.0001). The difference between the 10 mg E~4~ groups and the EE/DRSP group almost reached significance (*p =*0.0133).

[Table 2](#T0002){ref-type="table"} shows the mean and maximum FSH, LH, E~2~ and progesterone concentrations in treatment cycles 1, 2 and 3. Pooled FSH and LH concentrations on day 24 of cycle 1 and cycle 3 were significantly lower with increasing E~4~ dose (*p* \< 0.0001 and *p =*0.0078, respectively). There were no statistically significant differences in FSH and LH concentrations when the DRSP and the LNG groups were compared. Pooled FSH and LH concentrations on day 24 of cycle 1 and cycle 3 were significantly higher in the 5 mg E~4~ and 10 mg E~4~ groups than in the EE/DRSP group (*p* \< 0.0001).

###### Effects of treatment on pituitary--ovarian axis parameters^\*.^

  *Parameter*            *5 mg E4/DRSP (n = 17)*   *10 mg E4/DRSP (n = 19)*   *20 μg EE/DRSP (n = 20)*   *5 mg E4/LNG (n = 18)*   *10 mg E4/LNG (n = 17)*   *20 mg E4/LNG (n = 18)*                                                                         
  ---------------------- ------------------------- -------------------------- -------------------------- ------------------------ ------------------------- ------------------------- ------------- ------------- ------------- ------------- ------------- -------------
  LH, IU/l                                                                                                                                                                                                                                                   
   Baseline              4.84 (3.67)                                          5.83 (3.24)                                         4.31 (1.30)                                         4.47 (1.39)                 4.79 (1.72)                 4.08 (1.58)    
   Treatment cycle 1     5.50 (2.85)               7.28 (3.18)                6.26 (2.87)                8.55 (3.41)              3.38 (1.75)               5.43 (2.13)               5.77 (2.62)   8.05 (3.40)   5.52 (1.83)   8.01 (2.24)   3.15 (1.56)   4.87 (2.18)
   Treatment cycle 2     6.38 (3.95)               7.01 (3.65)                7.14 (3.89)                7.57 (3.68)              4.46 (2.40)               4.89 (2.73)               7.69 (4.78)   7.82 (4.73)   7.01 (2.71)   7.10 (2.81)   3.94 (1.81)   4.11 (1.98)
   Treatment cycle 3     5.69 (3.25)               7.92 (3.88)                6.77 (3.77)                8.92 (4.55)              2.77 (2.31)               5.01 (3.27)               5.71 (2.27)   8.49 (3.06)   5.89 (2.06)   8.51 (3.12)   4.13 (1.76)   6.44 (2.52)
  FSH, IU/l                                                                                                                                                                                                                                                  
   Baseline              6.23 (1.57)                                          6.71 (1.70)                                         5.82 (1.48)                                         5.50 (1.32)                 6.10 (2.08)                 5.12 (1.36)    
   Treatment cycle 1     6.66 (1.78)               7.91 (2.08)                6.39 (1.76)                7.64 (2.40)              4.19 (1.83)               5.94 (1.85)               5.82 (1.27)   7.22 (1.37)   6.17 (1.75)   7.56 (2.16)   3.67 (1.70)   4.58 (1.87)
   Treatment cycle 2     6.34 (1.65)               6.87 (1.67)                6.99 (1.66)                7.18 (1.42)              5.49 (1.95)               5.89 (2.16)               6.59 (1.73)   6.77 (1.69)   6.72 (1.75)   6.76 (1.78)   4.82 (1.75)   4.98 (1.76)
   Treatment cycle 3     6.59 (1.59)               8.35 (1.37)                6.63 (1.52)                7.89 (1.65)              3.14 (2.01)               5.72 (2.00)               5.75 (1.77)   7.06 (1.79)   5.97 (1.71)   7.50 (2.11)   4.60 (1.63)   6.18 (2.10)
  E~2~, pmol/l                                                                                                                                                                                                                                               
   Baseline              170 (210)                                            130 (60)                                            130 (170)                                           100 (60)                    120 (50)                    100 (50)       
   Treatment cycle 1     80 (30)                   120 (50)                   60 (20)                    110 (70)                 50 (20)                   140 (120)                 80 (60)       80 (40)       50 (20)       80 (40)       50 (10)       80 (60)
   Treatment cycle 2     200 (150)                 320 (350)                  140 (120)                  190 (220)                100 (150)                 170 (160)                 150 (90)      180 (170)     180 (170)     180 (170)     60 (50)       70 (110)
   Treatment cycle 3     120 (120)                 270 (270)                  110 (150)                  200 (260)                40 (10)                   280 (290)                 120 (110)     170 (110)     70 (40)       170 (110)     50 (10)       90 (90)
  Progesterone, nmol/l                                                                                                                                                                                                                                       
   Baseline              1.50 (0.54)                                          1.66 (0.87)                                         1.50 (0.42)                                         1.57 (0.48)                 1.69 (1.02)                 1.53 (0.69)    
   Treatment cycle 1     1.34 (0.34)               1.83 (0.49)                1.39 (0.46)                2.36 (1.14)              1.35 (0.41)               2.04 (0.64)               1.39 (0.39)   1.91 (0.53)   1.16 (0.35)   1.74 (0.57)   1.39 (0.55)   1.87 (0.79)
   Treatment cycle 2     1.30 (0.34)               1.47 (0.50)                1.16 (0.54)                1.20 (0.57)              1.25 (0.57)               1.34 (0.62)               1.34 (0.56)   1.36 (0.54)   1.10 (0.53)   1.11 (0.53)   1.50 (0.69)   1.51 (0.69)
   Treatment cycle 3     1.33 (0.30)               1.91 (0.54)                1.15 (0.39)                1.69 (0.73)              1.23 (0.48)               1.73 (0.72)               1.28 (0.34)   1.89 (0.61)   1.04 (0.35)   1.41 (0.50)   1.41 (0.54)   1.95 (0.79)

SD, standard deviation.

\*Mean (± SD) and maximum (mean ± SD) values exposed for all parameters measured during treatment cycles 1, 2 and 3.

Mean and maximum E~2~ concentrations decreased with increasing E~4~ concentration in the study medication combinations, and the lowest mean E~2~ concentration was observed in the 20 mg E~4~/LNG group (50 ± pmol/l at cycle 3) and was comparable to that of the EE/DRSP combination (40 ± 10 pmol/l at cycle 3). The pooled E~2~ concentrations on day 24 of cycle 1 and cycle 3 were significantly lower with increasing E~4~ dose (*p* \< 0.0001). There was no statistically significant difference in E~2~ concentrations between the DRSP and LNG groups. The pooled E~2~ levels on day 24 of cycles 1 and 3 were significantly higher in the 5 mg E~4~ groups than in the EE/DRSP group (*p =*0.0066 and *p =*0.0001, respectively); no significant difference was observed when comparing the 10 mg E~4~ groups and the EE/DRSP group (*p =*0.0708).

There were no discernible differences in mean or maximum progesterone concentrations among the treatment groups. All measured progesterone concentrations during treatment cycles 1, 2 and 3 were below 5 nmol/l, indicating absence of a LUF or ovulation, except for one measurement (a participant included in the 10 mg E~4~/DRSP group had a progesterone concentration of 5.69 nmol/l on day 3 of treatment cycle 1, probably due to incomplete regression of a corpus luteum from the pretreatment cycle). Progesterone concentrations did not statistically differ between the E~4~ groups and the EE/DRSP group, nor between the different E~4~ dose groups, nor between the DRSP and the LNG groups.

Endometrium {#S0013}
-----------

The mean endometrial thickness decreased in the treatment cycles compared with the pre- and post-treatment cycles, with no dose-related trends or significant differences between participants treated with increasing doses of E~4~ combined with DRSP or LNG ([Figure 4A, B](#F0004){ref-type="fig"}).

![Maximum (mean ± SD) endometrial thickness value observed for each group during the trial (A). Mean endometrial thickness assessed in each treatment group every 3 days across the pretreatment cycle, treatment cycles 1 and 3, and post-treatment cycle (B). D, day; Pre T, pretreatment cycle; Post T, post-treatment cycle.](iejc_a_1074675_f0004_b){#F0004}

Return of ovulation {#S0014}
-------------------

Return of ovulation was measured by monitoring follicular growth in the posttreatment cycle until ovulation occurred. During the post-treatment cycle, all participants ovulated within 21 days after stopping treatment. Those treated with 5 or 10 mg E~4~/DRSP had their first day of ovulation approximately 17 days after the last treatment (mean 17.6 and 17.1 days, respectively). The mean number of days to first ovulation was longer for participants treated with an E~4~/LNG combination (20.5, 20.8 and 21.0 days for the 5, 10 and 20 mg E~4~ groups, respectively). No difference was observed with increasing dose of E~4~. The mean number of days to first ovulation after the last active treatment with EE/DRSP was 20.6 days. The statistical analysis did not show any significant differences between the E~4~ groups and the EE/DRSP group, nor between the different E~4~ dose groups, nor between the DRSP and the LNG groups.

Safety and tolerability {#S0015}
-----------------------

The study combinations were well tolerated. No serious adverse events occurred. [Table 3](#T0003){ref-type="table"} shows the drug-related adverse events (i.e., considered possibly, probably or definitely related to treatment) reported by at least two participants in one of the treatment groups. Drug-related adverse events were reported by 50--82.4% of participants across the treatment groups. The most common drug-related adverse events were lower abdominal pain, nausea, headache, dysmenorrhoea, breast enlargement and acne. No overall trends were noted for the frequency of drug-related adverse events, when treatment groups were compared by dose of E~4~, between those treated with E~4~ and those treated with EE or between those treated with E~4~/DRSP or E~4~/LNG, except the incidence of headache, which was higher in participants treated with E~4~ compared with EE (not significantly different), and the incidence of acne, which was significantly higher in participants treated with E~4~/LNG compared with E~4~/DRSP.

###### Drug-related adverse events reported by at least two participants in any treatment group. Data expressed in number (%) of participants.

  *Parameter*              *5 mg E4/DRSP (n = 17)*   *10 mg E4/DRSP (n = 19)*   *20 μg EE/DRSP (n = 20)*   *5 mg E4/LNG (n = 18)*   *10 mg E4/LNG (n = 17)*   *20 mg E4/LNG (n = 18)*
  ------------------------ ------------------------- -------------------------- -------------------------- ------------------------ ------------------------- -------------------------
  Any adverse effect       13 (76.5)                 11 (57.9)                  12 (60.0)                  14 (77.8)                14 (82.4)                 9 (50.0)
  Lower abdominal pain     4 (23.5)                  1 (5.3)                    2 (10.0)                   1 (5.6)                  1 (5.9)                   0
  Nausea                   2 (11.8)                  2 (10.5)                   3 (15.0)                   1 (5.6)                  1 (5.9)                   2 (11.1)
  Irritability             0                         0                          2 (10.0)                   0                        0                         1 (5.6)
  Headache                 4 (23.5)                  6 (31.6)                   2 (10.0)                   4 (22.2)                 4 (23.5)                  4 (22.2)
  Dizziness                0                         0                          2 (10.0)                   0                        0                         1 (5.6)
  Affect lability          1 (5.9)                   0                          2 (10.0)                   1 (5.6)                  0                         0
  Decreased libido         0                         0                          1 (5.0)                    2 (11.1)                 1 (5.9)                   0
  Dysmenorrhoea            6 (35.3)                  3 (15.8)                   2 (10.0)                   1 (5.6)                  2 (11.8)                  2 (11.1)
  Breast enlargement       3 (17.6)                  2 (10.5)                   0                          0                        0                         1 (5.6)
  Breast tenderness/pain   2 (11.8)                  3 (15.8)                   3 (15.0)                   0                        1 (5.9)                   2 (11.1)
  Acne                     0                         1 (5.3)                    0                          3 (16.7)                 4 (23.5)                  3 (16.7)
  Seborrhoea               0                         0                          0                          1 (5.6)                  2 (11.8)                  0
  Hot flush                2 (11.8)                  0                          0                          0                        0                         0

DISCUSSION {#S0016}
==========

Findings and interpretation {#S0017}
---------------------------

The results of this study demonstrate that E~4~ in combination with DRSP or LNG effectively inhibits ovulation. There were no ovulations or LUFs during the treatment cycles in all treatment groups, showing the efficacy of 5, 10 and 20 mg E~4~ combined with DRSP or LNG in a regimen of 24-treatment days followed by a 4-day treatment-free period.

Ovarian suppression, as determined by maximum follicular diameter, mean and maximum E~2~ concentration and Hoogland score, was adequate in all E~4~ treatment groups. There were no discernible differences in the degree of ovarian suppression between the two progestins. However, a difference could be observed between the different E~4~ doses. Ovarian suppression was most pronounced at the highest E~4~ dose (20 mg E~4~). In addition, suppression of gonadotropins was most pronounced in the highest dosage group. The stronger ovarian and pituitary suppression in this group could already be observed in the first treatment cycle and was more apparent in the third treatment cycle. Ovarian suppression in the 20 mg E~4~/LNG group was comparable to that in the EE/DRSP group, and also with ovarian suppression reported with other registered COCs containing EE or E~2~ ^[@CIT0015]^.

Endometrial thickness was reduced in the treatment cycles compared with the pre- and post-treatment cycles. The results were comparable in all treatment groups, including the EE/DRSP group. Apparently, E~4~ in combination with a progestin has a similar effect on endometrial growth to that of EE/DRSP.

The first post-treatment ovulation occurred approximately 17 days after the last treatment day in the E~4~/DRSP groups, and 21 days after the last active treatment in the E~4~/LNG and EE/DRSP groups. An explanation for the difference between the two progestins cannot be given. For all treatment groups, the time period until the first ovulation was comparable to the duration of a normal follicular phase, confirming adequate ovarian suppression during treatment.

The different combinations were safe and well tolerated. The reported adverse events were the same as those previously described with other marketed COCs. When comparing both progestins, the incidence of headache was higher in the E~4~/DRSP groups, whereas the incidence of acne was higher in the E~4~/LNG groups. No E~4~ dose-related trends could be observed in the frequency or severity of the reported adverse events.

Strengths and weaknesses of the study {#S0018}
-------------------------------------

This study represents the first attempt to combine E~4~ and LNG or DRSP to achieve blockade of ovulation for three cycles. The study was conducted using state-of-the-art methodologies and by an experienced scientific team. Even if the number of participants included in each treatment arm was limited, the primary objective of the study was achieved, as no ovulation occurred in any patient.

Because the primary objective of this exploratory study was to evaluate ovulation inhibition in the different groups, the sample size was not powered to perform a safety comparison between the tested combinations. Therefore, larger studies will be needed to confirm the safety profile and tolerability of an E~4~-containing COC.

Differences in the results and conclusions {#S0019}
------------------------------------------

Animal studies performed in female rats, and human studies performed in postmenopausal women, have already demonstrated the significant dose-dependent inhibitory effect of E~4~ on central gonadotropin secretion^[@CIT0003],[@CIT0023]^. The results of the present study confirm these previous data, as with a fixed dose of progestin higher doses of E~4~ were associated with a more profound inhibition of ovarian activity.

A previous study showed that the 24/4-day regimen is associated with greater inhibition of ovarian function than the conventional 21/7-day regimen^[@CIT0026]^. Administering the E~4~ combinations following that regimen might also have contributed to the total absence of Hoogland scores 5 and 6 in our study.

Finally, recent physiological studies reveal critical requirements for membrane ERα in ovarian function and thereby in fertility^[@CIT0027]^. Transgenic mice lacking the membrane ERα do not ovulate, demonstrating that this receptor is essential for ovulation. E~4~ selectively activates the nuclear ERα but antagonises the membrane ERα^[@CIT0028]^. This selective blockade of the membrane ERα could contribute to the blockade of ovulation.

Relevance of the findings: Implications for clinicians {#S0020}
------------------------------------------------------

Women with intermenstrual bleeding have significantly larger FLS and significantly higher E~2~ levels than those without intermenstrual bleeding. High ovarian suppression is classically positively correlated with improved cycle control characterised by less frequent intermenstrual bleeding^[@CIT0029]^. When administered at a dosage above 10 mg/day, E~4~ appears to be a promising alternative estrogen for use in contraception. Because doses of 20 mg E~4~ combined with a progestin suppress ovarian activity as efficiently as 20 μg EE/DRSP or other registered COCs containing EE or E~2~, an additional phase II study should be able to more precisely delineate the best E~4~ dose regimen between 10 and 20 mg that provides an acceptable pattern of intermenstrual spotting and bleeding.

E~4~ exhibits several unique features that could make it suitable as an alternative estrogen for use in a COC. These advantages were evaluated in previous trials and have been reported elsewhere. First, E~4~ has a high oral bioavailability associated with a long half-life of approximately 30 h, allowing daily administration. Furthermore, E~4~ is an end-product of estrogen metabolism in the human foetus. Metabolism through oxidation does not occur. In non-pregnant women, E~4~ is rapidly and almost completely excreted in the urine as a conjugate (glucuronide and sulphate). In contrast to EE and E~2~, E~4~ is less subject to biliary excretion and enterohepatic recirculation^[@CIT0030]^. Therefore, it is tempting to speculate that COCs containing E~4~ would not result in an increased risk of hepatobiliary diseases as observed among users of EE-containing medications^[@CIT0009]^. Furthermore, because E~4~ has a minimal impact on production of coagulation factors in the liver, the VTE risk might also be reduced compared with EE-containing COCs \[Kluft C. *et al.*, submitted\].

Unanswered questions and future research {#S0021}
----------------------------------------

In addition to ovulation inhibition, it is necessary to assess tolerability and bleeding pattern when defining the adequate dosage of a new estrogen to be incorporated in a COC. The present study, with its relatively small sample size and short treatment duration, was not designed to evaluate properly the bleeding pattern and safety aspects of the different combinations tested. A larger dose-finding study aiming at assessing the tolerability, acceptability and bleeding characteristics of different E~4~-containing combinations is therefore necessary.

As mentioned above, larger trials will also be needed to fully characterise the contraceptive efficacy and safety profile of an E~4~-containing COC among women of different ethnicities, with different health-related characteristics (e.g., BMI, smoking habits) and of different ages. Only large and sufficiently long-term studies will be able to answer these questions.

CONCLUSION {#S0022}
==========

The results of this study show that E~4~ in combination with DRSP or LNG adequately suppresses ovarian activity and inhibits ovulation, particularly when given at a dosage above 10 mg/day. E~4~ appears to be a promising alternative estrogen for use in contraception.
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